Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)

• Company Description    Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California. Number of Employees: 317

• Price / Volume Information    Yesterday's Closing Price: $23.38 Daily Weekly Monthly 20 Day Moving Average: 1,524,139 shares Shares Outstanding: 103.78 (millions) Market Capitalization: $2,426.42 (millions) Beta: 1.80 52 Week High: $25.09 52 Week Low: $8.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.10% 3.33% 12 Week 40.00% 36.17% Year To Date 23.25% 15.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1600 SIERRA POINT PKWY - BRISBANE,CA 94005 USA ph: 415-660-5320 fax: - kfortner@nurixtx.com http://www.nurixtx.com

• General Corporate Information    Officers Arthur T. Sands - President and Chief Executive Officer Julia P. Gregory - Chairman Hans van Houte - Chief Financial Officer Roy D. Baynes - Director Roger Dansey - Director Peer Information Nurix Therapeutics, Inc. (CORR.) Nurix Therapeutics, Inc. (RSPI) Nurix Therapeutics, Inc. (CGXP) Nurix Therapeutics, Inc. (BGEN) Nurix Therapeutics, Inc. (GTBP) Nurix Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67080M103 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: 05/01/26 Next Expected EPS Date: 10/08/26 Share - Related Items Shares Outstanding: 103.78 Most Recent Split Date: (:1) Beta: 1.80 Market Capitalization: $2,426.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.82 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/08/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.03 Price/Cash Flow: - Price / Sales: 66.00 EPS Growth vs. Year Ago Period: -55.77% vs. Previous Quarter: -2.53% Sales Growth vs. Year Ago Period: -79.47% vs. Previous Quarter: 44.64% ROE 05/31/26 - -76.09 02/28/26 - -64.21 11/30/25 - -57.51 ROA 05/31/26 - -57.31 02/28/26 - -48.44 11/30/25 - -43.76 Current Ratio 05/31/26 - 6.34 02/28/26 - 6.01 11/30/25 - 7.02 Quick Ratio 05/31/26 - 6.34 02/28/26 - 6.01 11/30/25 - 7.02 Operating Margin 05/31/26 - -928.44 02/28/26 - -411.37 11/30/25 - -314.90 Net Margin 05/31/26 - -928.44 02/28/26 - -411.37 11/30/25 - -314.90 Pre-Tax Margin 05/31/26 - -929.18 02/28/26 - -410.32 11/30/25 - -314.00 Book Value 05/31/26 - 3.88 02/28/26 - 4.65 11/30/25 - 5.29 Inventory Turnover 05/31/26 - - 02/28/26 - - 11/30/25 - - Debt-to-Equity 05/31/26 - 0.00 02/28/26 - 0.00 11/30/25 - 0.00 Debt-to-Capital 05/31/26 - 0.00 02/28/26 - 0.00 11/30/25 - 0.00

Powered by Zacks Investment Research ©